Abstract 372P
Background
The therapeutic targets of pancreatic cancer (PC) are fewer. Cell-free DNA (cfDNA) has been a research hotspot in molecular tumour profiling. In advanced PC patients, malignant abdominal dropsy provides a wealth of tumour cells that can be investigated. The aim of this study is to investigate fusion landscape in advanced PC.
Methods
A multicenter study in China was initiated from Oct. 2016, and PC patients have been enrolled as of Apr. 2019. To determine the fusion frequency in PC, we analysed data from 536 clinical PC cases, each of which had results from next-generation sequencing (NGS)-based 808 genes panel assay, analogous to the index patient.
Results
Of this entire cohort, 24 patients (4.48%) were identified with fusions, including ARID1A-PIGV (1), HSD3BP4-HSD3B1 (1), CDKN2A-MTAP (1), PDE10A-BRAF (1), ETV6-NTRK3 (1), NOTCH1-RABL6 (1), ERRFI1-SLC25A33 (1),BRCA1-PTGES3L (1),MYCN-LINC00299 (1), CREBBP-CDIP1 (1), LPAR5-CHD4 (1), PMS2-ETV1 (1), RPTOR-ASPSCR1 (1), CHD2-SLCO3A1 (1), IDH2-SEMA4B (1), BAIAP2-RPTOR (1), CHEK1-OSBP (1), LRP1-KRT81 (1), TBX3-ACSS3 (1), RAB11FIP1-GPR124 (1), AXIN1-SNX29 (1), PPP2R1A-ZNF415 (1), BCL2L14-ETV6 (1) and BMX-NHS (1). BRAF, NTRK and BRCA1 fusions were seen in 12.50% (3/24) advanced Chinese pancreatic cancer fusion landscape patients. These three patients were diagnosed with pancreatic duct adenocarcinoma. For treatments, the BRAF fusion patient chose vemurafenib, another two patients chose chemotherapy, and this case of BRAF fusion patient responding to vemurafenib was actively being sought thru our database.
Conclusions
Advanced Chinese pancreatic cancer fusion landscape is rich, BRAF and NTRK fusions are rare but potentially druggable in TKIs. Detection of BRAF, NTRK, BRCA1, EGFR, ALK, ROS1, RET and ERBB2 fusions should be part of comprehensive profiling panels to determine TKIs and direct appropriate combination therapeutic strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yiyu Shen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO31 - Primary pulmonary sarcoma
Presenter: Khilola Ubaydullaeva
Session: Poster display session
Resources:
Abstract
YO32 - prostatic rhabdomyosarcoma in an adult patient: A case study
Presenter: Muhammad Rafiqul Islam
Session: Poster display session
Resources:
Abstract
YO33 - Hyponatremia – slaying the dragon or chasing a mirage- a Case report
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
YO34 - A rare endocrinological syndrome presenting with weakness in Soft tissue sarcoma - a Case report
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
YO35 - Gefitinib induced movement disorder - a Case report
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
YO36 - A case of BRAF V600E mutated non-small-cell lung cancer with pleomorphic features
Presenter: Reiko Matsuzawa
Session: Poster display session
Resources:
Abstract
YO37 - Intraventricular metastasis as the first presentation of non-small cell lung cancer
Presenter: Siraphong Putraveephong
Session: Poster display session
Resources:
Abstract
YO38 - Cerebral metastases from a thymic malignancy: a case report
Presenter: Marfu'au Nik Eezamuddeen
Session: Poster display session
Resources:
Abstract
YO39 - Primary Follicular Thyroid Carcinoma Metastatic to the Kidney Mimicking Renal Cell Carcinoma: A Case Report
Presenter: Jestoni Aranilla
Session: Poster display session
Resources:
Abstract
YO40 - A Rare Case of Primary Malignant Giant Cell Tumor of Tibia
Presenter: Gowthami Venugopal
Session: Poster display session
Resources:
Abstract